Form 8-K - Current report:
SEC Accession No. 0001213900-25-000844
Filing Date
2025-01-03
Accepted
2025-01-03 17:21:37
Documents
14
Period of Report
2024-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226635-8k_osthera.htm   iXBRL 8-K 44795
2 PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON DECEMBER 31, 2024 ea022663501ex99-1_osthera.htm EX-99.1 17079
  Complete submission text file 0001213900-25-000844.txt   248041

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ostx-20241231.xsd EX-101.SCH 3024
4 XBRL LABEL FILE ostx-20241231_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE ostx-20241231_pre.xml EX-101.PRE 22365
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0226635-8k_osthera_htm.xml XML 3807
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

IRS No.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42195 | Film No.: 25507917
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)